Physician profile
Christopher J Everett
NPI 1700140365
$486.02
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2022: $204 · 2023: $33.80 · 2024: $82.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $142.43 | 2022 | |
| Janssen Pharmaceuticals, INC | $61.97 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $46.35 | 2024 | Cobenfy |
| Merck Sharp & Dohme LLC | $43.51 | 2019 | |
| Pfizer INC. | $37.59 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $32.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.37 | 2019 | |
| Intuitive Surgical, INC. | $20.72 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $19.27 | 2019 | |
| Gilead Sciences, INC. | $17.52 | 2023 | |
| Insmed, INC. | $16.28 | 2023 | Arikayce |
| Tactile Systems Technology INC | $14.96 | 2024 | Entre Plus, Flexitouch Plus |
| Glaxosmithkline, LLC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.